Press Release: European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya

Author (Corporate)
Series Title
Series Details EMA/263105/2012 (20.4.12)
Publication Date 20/04/2012
Content Type

The European Medicines Agency (EMA), on 20 April 2012, gave new advice to healthcare professionals to reduce the risk of adverse effects on the heart associated with the use of the multiple sclerosis (MS) treatment Gilenya (fingolimod).
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001498.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/263105/2012 (20.4.12): European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/04/WC500125690.pdf
Subject Categories
Countries / Regions